Drug programs

The drug program is a guaranteed service, i.e., financed from NFZ (National Health Fund)

Treatment under the programme uses innovative and costly active substances which are not financed under other guaranteed benefits. Treatment is carried out in selected disease entities and covers a strictly defined group of Patients. Patients are qualified for the drug programme by a physician from a centre contracted to carry out a specific programme, based on detailed programme eligibility criteria. Patients qualified for drug programmes are treated free of charge.

The description of the drug programme includes:

• Patient qualification criteria for treatment.
• Exclusion criteria from the program.
• Drug dosing schedule.
• Drug administration method.
• A list of diagnostic tests performed when qualifying a patient for the program and those necessary for treatment monitoring.

NU-MED Specialised Oncology Hospital in Tomaszów Mazowiecki implements the following drug programs:

DRUG PROGRAM - TREATMENT OF PATIENTS WITH SOLID TUMORS WITH NEUROTROPHIN RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION           DRUG PROGRAM - TREATMENT OF PATIENTS WITH SYSTEMIC LIGHT CHAIN AMYLOIDOSIS (AL)                                        
DRUG PROGRAM - TREATMENT OF PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA                                            
DRUG PROGRAM - TREATMENT OF PATIENTS WITH ENDOMETRIAL CANCER                                                    
DRUG PROGRAM - TREATMENT OF PATIENTS WITH CERVICAL CANCER                                                    
DRUG PROGRAM - TREATMENT OF PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE SKIN                                        
DRUG PROGRAM - TREATMENT OF PATIENTS WITH NEUROENDOCRINE TUMORS OF THE GASTROINTESTINAL TRACT WITH THE USE OF RADIOPHARMACEUTICALS                
DRUG PROGRAM - TREATMENT OF PATIENTS WITH UROTHELIAL CARCINOMA                                                    
DRUG PROGRAM - TREATMENT OF PATIENTS WITH COLORECTAL CANCER    
DRUG PROGRAM - TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA                                                
DRUG PROGRAM - TREATMENT OF PATIENTS WITH LUNG CANCER AND PLEURAL MESOTHELIOMA                                            
DRUG PROGRAM - TREATMENT OF PATIENTS WITH SOFT TISSUE SARCOMAS                                                    
DRUG PROGRAM - TREATMENT OF PATIENTS WITH BREAST CANCER                                                        
DRUG PROGRAM - TREATMENT OF PATIENTS WITH KIDNEY CANCER                                                        
DRUG PROGRAM - TREATMENT OF PATIENTS WITH B-CELL LYMPHOMAS                                                
DRUG PROGRAM - TREATMENT OF PATIENTS WITH OVARIAN CANCER, FALLOPIAN TUBE CANCER OR PERITONEAL CANCER                                        
DRUG PROGRAM - TREATMENT OF SQUAMOUS CELL CANCER OF THE HEAD AND NECK ORGANS                                            
DRUG PROGRAM - TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA                                                
DRUG PROGRAM - TREATMENT OF PATIENTS WITH PROSTATE CANCER    
DRUG PROGRAM - TREATMENT OF PATIENTS WITH ESOPHAGEAL, GASTROESOPHAGEAL JUNCTION AND GASTRIC CANCER                                
DRUG PROGRAM - TREATMENT OF PATIENTS WITH MELANOMA OF THE SKIN OR MUCOUS MEMBRANES                                            
DRUG PROGRAM - TREATMENT OF PATIENTS WITH T-CELL LYMPHOMAS                                                
DRUG PROGRAM - TREATMENT OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA                                                
DRUG PROGRAM - TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA                                            
DRUG PROGRAM - TREATMENT OF PATIENTS WITH PANCREATIC ADENOCARCINOMA                                                
DRUG PROGRAM - TREATMENT OF PATIENTS WITH MEDULLARY THYROID CANCER                                                
DRUG PROGRAM - TREATMENT OF MERKEL CELL CARCINOMA WITH AVELUMAB                                                
DRUG PROGRAM - TREATMENT OF PATIENTS WITH DIFFERENTIATED THYROID CANCER                                            
DRUG PROGRAM - PREVENTION OF BONE COMPLICATIONS IN ADULT PATIENTS WITH ADVANCED BONE CANCER WITH DENOSUMAB